IPDMA 

CFTR corrector and potentiator

Phase of research

Pre-clinical

How it helps

Restore CFTR Function

General information

IPDMA is an experimental substance used in studies and not yet available as a human pharmaceutical. It was created as a derivate of a triple-acting compound TMA, which shows anti-inflammatory activity in addition to CFTR corrector and potentiator properties, but is mutagenic. In relation to cystic fibrosis, our AIM tool found the data that IPDMA can be effective in both correcting F508del-CFTR and potentiating CFTR-dependent chloride transport in G551D mutants. 

Synonyms

4-isopropyl-6,4′-dimethylangelicin

Marketed as

N/A

Dietary sources

N/A

Structure image not available

N/A

Drug-Mutation Relation

Treats

Mutation Number of sources Average impact factor
F508del
1 3.85
Link Tested on Impact factor Notes
Molecular Mechanism of Action of Trimethylangelicin Derivatives as CFTR Modulators human cell cultures 3.85 Less effective than TMA or lumacaftor.
G551D
1 3.85
Link Tested on Impact factor Notes
Molecular Mechanism of Action of Trimethylangelicin Derivatives as CFTR Modulators human cell cultures 3.85 Comparable to genistein.

Does not treat

Mutation Number of sources Average impact factor